GZMB and COVID-19: In support of our findings related to IL-6 and granzyme B as biomarkers of liver injury, a recent study demonstrated that IL-6 trans-signaling drives COVID-19-associated hepatic endotheliopathy, which is suggested as a possible mechanism underlying the liver injury (29).